Cite
Corrigendum to "N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression"[Eur. J. Med. Chem. 2020 Jan 1;185:111725].
MLA
Mehndiratta, Samir, et al. “Corrigendum to ‘N-Alkyl-Hydroxybenzoyl Anilide Hydroxamates as Dual Inhibitors of HDAC and HSP90, Downregulating IFN-γ Induced PD-L1 Expression’[Eur. J. Med. Chem. 2020 Jan 1;185:111725].” European Journal of Medicinal Chemistry, vol. 199, Aug. 2020, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejmech.2020.112406.
APA
Mehndiratta, S., Lin, M.-H., Wu, Y.-W., Chen, C.-H., Wu, T.-Y., Chuang, K.-H., Chao, M.-W., Chen, Y.-Y., Pan, S.-L., Chen, M.-C., & Liou, J.-P. (2020). Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725]. European Journal of Medicinal Chemistry, 199, N.PAG. https://doi.org/10.1016/j.ejmech.2020.112406
Chicago
Mehndiratta, Samir, Mei-Hsiang Lin, Yi-Wen Wu, Chun-Han Chen, Tung-Yun Wu, Kuo-Hsiang Chuang, Min-Wu Chao, et al. 2020. “Corrigendum to ‘N-Alkyl-Hydroxybenzoyl Anilide Hydroxamates as Dual Inhibitors of HDAC and HSP90, Downregulating IFN-γ Induced PD-L1 Expression’[Eur. J. Med. Chem. 2020 Jan 1;185:111725].” European Journal of Medicinal Chemistry 199 (August): N.PAG. doi:10.1016/j.ejmech.2020.112406.